[Application of tacrolimus and cyclosporine A in HBV-carrying renal transplant recipients].
OBJECTIVE
To compare the long-term effect and safety of tacrolimus (FK506) and cyclosporine (CsA) in kidney transplant (KT) recipients carrying hepatitis B Virus(HBV).


METHODS
A total of 109 patients with HBV were randomized into FK506 group (52 cases) and CsA group (57 cases) after KT, and a 2-year-long follow-up of the patients was conducted to record the patient and graft survival, incidence of acute graft rejection and postoperative liver function.


RESULTS
The 2-year patient/graft survival was 86.0%/73.7% and 94.2%/90.3% in CsA and FK506 groups, respectively (P<0.05), with incidence of acute rejection of 10.5% and 9.6% (P>0.05), and rate of abnormal liver function of 26.3% and 15.4% (P<0.05), respectively. Eight patients (14.4%) in CsA group required a drug conversion but none in FK506 group. The drug conversion resulted in significant reduction of ALT/AST level from 255.13+/-31.38/201.88+/-21.25 U/L to 31.25+/-11.50/25.13+/-9.68 U/L (P<0.01).


CONCLUSIONS
For HBV-carrying renal transplant recipients, FK506 as the primary choice of immunosuppressant can be more effective and safer than CsA.
Liu
Xiao-you
XY
Department of Kidney Transplantation, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Yu
Li-xin
LX
Fu
Shao-jie
SJ
Xu
Jian
J
Du
Chuan-fu
CF
Deng
Wen-feng
WF
Wang
Yi-bin
YB
Ye
Gui-rong
GR
Zhang
Yan-xuan
YX
D000293:Adolescent; D000328:Adult; D002353:Carrier State / Q000503:physiopathology; D016572:Cyclosporine / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology*; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006084:Graft Rejection; D006514:Hepatitis B Surface Antigens / Q000378:metabolism; D006515:Hepatitis B virus; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects; D008099:Liver / Q000187:drug effects / Q000502:physiology; D008297:Male; D008875:Middle Aged; D016559:Tacrolimus / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology*; D055815:Young Adult
D006514:Hepatitis B Surface Antigens; D016572:Cyclosporine; D016559:Tacrolimus